A Huntsman Cancer Institute team at the University of Utah reports that daraxonrasib, a targeted RAS inhibitor, could offer a new treatment route for a subset of melanoma patients whose tumors are driven by NRAS mutations. The work addresses an ongoing clinical gap: effective targeted options for NRAS-mutant metastatic melanoma have been limited, leaving many … Continue reading New drug candidate offers hope for patients with NRAS-driven melanoma